Fierce BioBiotech
AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
21 Apr 20260 views
Summary
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s frontrunners.
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s frontrunners.